Uptake of the HPV vaccine among people with and without HIV, cisgender and transgender women and men who have sex with men and with women at two sexual health clinics in Mexico City

Figures & data

Table 1. Selected socio-demographic characteristics of the study population, recruited at two sexual health, HIV treatment and transgender health clinics in Mexico City, Mexico, 2018.

		Gender identity
Characteristics	Study Population ^§ n = 1,915	Women 396 (20.7)	Men 1341 (70.0)	Transwomen 178 (9.3)
Age (Mean ± SD)	29.4 ± 7.6	30.4 ± 7.5	28.7 ± 7.3	32.6 ± 9.0
Years of education (Mean ± SD)	13.9 ± 11.0	12.7 ± 4.3	14.5 ± 4.0	11.7 ± 3.9
Marital status
Married/partnered	447 (23.3)	125 (31.6)	274 (20.4)	48 (27.0)
Single	1460 (76.2)	267 (67.4)	1063 (79.3)	130 (73.0)
No response	8 (0.5)	4 (1.0)	4 (0.3)	-
Living with HIV (Self-reported)
No	1278 (66.7)	357 (90.2)	785 (58.5)	136 (76.4)
Yes	615 (32.1)	36 (9.0)	537 (40.0)	42 (23.6)
No response	22 (1.2)	3 (0.8)	19 (1.5)	-
History of STIs (Self-reported)^f
No	851 (44.4)	262 (66.2)	489 (36.5)	100 (56.2)
Yes	1039 (54.3)	124 (31.3)	838 (62.5)	77 (43.3)
No response	25 (1.3)	10 (2.5)	14 (1.0)	1 (0.5)
Age at first sexual (vaginal or anal) intercourse
(Mean, years ± SD)	17.9 ± 8.7	19.2 ± 11.0	17.8 ± 7.6	16.4 ± 10.9
Ever done sex work
No	1502 (78.5)	325 (82.0)	1018 (76.0)	159 (89.3)
Yes	403 (21.0)	67 (17.0)	318 (23.7)	18 (10.1)
No response	10 (0.5)	4 (1.0)	5 (0.3)	1 (0.6)
Number of sexual partners in the last 3 months
1	617 (32.2)	192 (48.5)	370 (27.6)	55 (31.9)
2–5	746 (39.0)	116 (29.3)	583 (43.5)	47 (26.4)
>5	321 (16.8)	36 (9.1)	243 (18.1)	42 (23.6)
No response	231 (12.0)	52 (13.1)	145 (10.8)	34 (19.1)

*HPV vaccine uptake was defined as when the study participant agreed to receive the first dose of the HPV vaccine and also actually received that first dose. In these groups, the women and men are cis gender or non-trans. SD: Standard Deviation. fSexually transmitted infections (chlamydia, gonorrhea, syphilis, trichomoniasis, hepatitis B or C)

§The total sample included 396 cisgender (or nontrans) women, 178 transwomen and 1341 men, of whom 1247 were men who have sex with men and 94 were men who had sex with women.

Table 2. HPV vaccine uptake in adults, recruited at two sexual health, HIV treatment and transgender health clinics in Mexico City, Mexico, 2018.

	HPV vaccine uptake*
Characteristics	No 209 (10.9)	Yes 1706 (89.1)	P value
Gender identity
Women	72 (18.2)	324 (81.8)	<.001
Men	114 (8.5)	1227 (91.5)
Transwomen	23 (13.0)	155 (87.0)
Age
14–24 years	52 (9.2)	514 (90.8)	.2
25–34 years	103 (11.6)	786 (88.4)
35+ years	54 (11.8)	404 (88.2)
No response	-	2 (100.0)
Years of education
0–12 years	101 (13.5)	647 (86.5)	.008
13–17 years	73 (9.1)	726 (90.8)
18 or more years	29 (8.6)	308 (91.4)
No response	6 (19.3)	25 (80.7)
Marital status
Single	144 (9.9)	1316 (90.1)	0.01
Married/partnered	63 (14.0)	384 (86.0)
No response	2 (25.0)	6 (75.0)
Living with HIV (Self-reported)
No	146 (11.4)	1132 (88.6)	.5
Yes	61 (9.9)	554 (90.1)
No response	2 (9.0)	20 (91.0)
History of STIs (Self-reported)§
No	100 (11.8)	751 (88.2)	.5
Yes	107 (10.3)	932 (89.7)
No response	2(8.0)	23 (92.0)
Has done sex work
No	179 (12.0)	1323 (88.0)	.01
Yes	28 (7.0)	375 (93.0)
No response	2 (20.0)	8 (80.0)
Number of sexual partners in the last 3 months
1	84 (13.6)	533 (86.4)	.03
2–5	75 (10.0)	671 (90.0)
>5	25 (7.8)	296 (92.2)
No response	25 (10.8)	206 (89.2)

*HPV vaccine uptake was defined as when the study participant agreed to receive the first dose of the HPV vaccine and also actually received that first dose. These are cis gender or non-trans women. SD: Standard Deviation. § Sexually transmitted infections (chlamydia, gonorrhea, syphilis, trichomoniasis, hepatitis B or C).

Table 3. Variables associated with HPV vaccine uptake among adults recruited from two sexual health, HIV treatment and transgender health clinics Mexico City, Mexico, 2018.

	HPV vaccine uptake*
Variables	Crude OR	95% CI	Adjusted OR**	95% CI
Sociodemographic characteristics
Gender identity
Men	1	-	1	-
Transwomen	0.62	(0.38–1.01)	0.61	(0.37–1.00)
Women	0.41	(0.30–0.57)	0.43	(0.30–0.61)
Age
14–24 years	1	-	1	-
25–34 years	0.77	(0.54–1.09)	0.75	(0.52–1.08)
35+ years	0.75	(0.50–1.13)	0.77	(0.50–1.16)
Years of education
0–12 years	1	-	1	-
13–17 years	1.55	(1.12–1.13)	1.51	(1.09–2.10)
18+ years	1.65	(1.07–2.56)	1.54	(0.99–2.39)
Marital status
Single	1	-	1	-
Married/partnered	0.6	(0.48–0.88)	0.70	(0.51–0.97)
Living with HIV (Self-reported)
No	1	-	1	-
Yes	1.16	(0.86–1.56)	1.17	(0.86–1.61)
History of STIs (Self-reported)§
No	1	-	1	-
Yes	1.16	(0.87–1.55)	1.09	(0.78–1.52)
Ever done sex work
No	1	-	1	-
Yes	1.72	(1.15–2.58)	1.70	(1.12–2.56)
Number of sexual partners in the last 3 months
1	1	-	1	-
2–5	1.40	(1.01–1.96)	1.31	(0.93–1.84)
>5	1.58	(1.09–2.29)	1.44	(0.98–2.11)

*HPV vaccine uptake was defined as when the study participant agreed to receive the first dose of the HPV vaccine and also actually received that first dose. § Sexually transmitted infections (chlamydia, gonorrhea, syphilis, trichomoniasis, hepatitis B or C)

** The model was adjusted for the following variables: marital status, self-reported HIV positivity and number of sexual partners in the last 3 months